1. Acknowledgement to Referees

   Acknowledgement to Referees 19 November 2021 Pages: 2077 - 2080

2. Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence

   • Shelley N. Facente
   • Angela M. Reiersen
   • Jeffrey D. Klausner

   Current Opinion Open access 01 December 2021 Pages: 2081 - 2089

   

3. Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A

   • Nowell Solish
   • Jean Carruthers
   • Conor J. Gallagher

   Leading Article Open access 17 November 2021 Pages: 2091 - 2101

   

4. Cannabis-Based Medicines and Medical Cannabis in the Treatment of Nociplastic Pain

   • Mary-Ann Fitzcharles
   • Frank Petzke
   • Winfried Häuser

   Review Article 20 November 2021 Pages: 2103 - 2116

5. The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: An Update

   • Dan Reynolds
   • Marin Kollef

   Review Article 07 November 2021 Pages: 2117 - 2131

   

6. Regdanvimab: First Approval

   • Yahiya Y. Syed

   AdisInsight Report 01 November 2021 Pages: 2133 - 2137

   

7. Correction to: Regdanvimab: First Approval

   • Yahiya Y. Syed

   Correction 16 November 2021 Pages: 2139 - 2139

8. Tisotumab Vedotin: First Approval

   • Anthony Markham

   AdisInsight Report 08 November 2021 Pages: 2141 - 2147

   

9. Abrocitinib: First Approval

   • Emma D. Deeks
   • Sean Duggan

   AdisInsight Report Open access 22 November 2021 Pages: 2149 - 2157

   

10. Penpulimab: First Approval

    • Sohita Dhillon

    AdisInsight Report 23 November 2021 Pages: 2159 - 2166

    

11. Correction to: Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections

    • Yahiya Y. Syed

    Correction Open access 18 November 2021 Pages: 2167 - 2167

12. Correction to: Avatrombopag: A Review in Thrombocytopenia

    • Anthony Markham

    Correction Open access 29 November 2021 Pages: 2169 - 2169